PZA Innovation

What PZA Innovation does

PZA Innovation LLC is a Baltimore-based biotechnology company founded in 2020 that develops diagnostic products for pyrazinamide (PZA) susceptibility testing in Mycobacterium tuberculosis. The company's central technical claim is a broth microdilution method (BMM) executed at neutral pH 6.8 — replacing the conventional acidic conditions (pH 5.0–5.5) that the company argues produce unreliable results by inhibiting M. tuberculosis growth. This neutral-pH platform addresses a documented clinical gap: approximately 1.4 million new PZA-resistant TB cases occur annually and no widely available reliable PZA susceptibility test exists today.

The product portfolio consists of three catalog items sold For Research Use Only: the PZA DST Kit (PZA2026V2S), a dry-format 96-well MIC plate using visible-growth interpretation with results in 7–21 days; the MycoGI PZA DST Kit (PZA2026V2C), which integrates an oxygen-quenched fluorescence sensor for objective, earlier endpoint reading in 6–10 days and detection of 1% resistant subpopulations versus the 10% threshold of conventional methods; and the Manual Microplate Fluorescence Viewbox (PZA2026MV), a mirrored accessory for manual fluorescence plate reading. Scientific validation is anchored in peer-reviewed publications, including a 2021 paper in Antibiotics and a 2025 co-authored paper in Frontiers in Microbiology.

The company operates a sales-led, direct catalog distribution model targeting clinical diagnostic laboratories (primary segment) and academic/government TB research institutions (secondary). All funding to date has been non-dilutive: an NSF SBIR Phase I award in January 2022, an MBIA Commercialization Impact Grant in November 2023, and a $1.68 million NIH NIAID Direct-to-SBIR Phase II grant (R44AI181252) in January 2024. PZA Innovation has been a member of the LifeBridge Health BioIncubator since 2020 and is collaborating with two unnamed research institutes on the NIAID-funded project.

Name

PZA Innovation

Legal name

PZA Innovation LLC

Website

https://pzainnovation.com

Company type

Private

Founded year

2020

Operating status

Operating

Short description

PZA Innovation LLC is a Baltimore-based biotechnology company developing neutral-pH broth microdilution diagnostic kits for pyrazinamide susceptibility testing in Mycobacterium tuberculosis, selling research-use catalog products to clinical laboratories and TB research institutions.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (Tuberculosis Susceptibility Testing)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Quality Control (QC) Testing Technologies for Biomanufacturing (release/stability assays, rapid microbiology) (HLAAAJAK)

akta.pro secondary industry

Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)

Keywords

• Tuberculosis diagnostics
• Drug susceptibility testing
• In vitro diagnostics
• Microbiology testing kits
• Pyrazinamide resistance testing

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Diagnostic Testing Kits: Sale of PZA susceptibility testing products including PZA DST Kit (PZA2026V2S) and MycoGI PZA DST Kit (PZA2026V2C) to laboratories and research institutions
2. Laboratory Equipment: Sale of Manual Microplate Fluorescence Viewbox (PZA2026MV) for fluorescence-based growth interpretation in MycoGI DST products

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

PZA Innovation LLC develops and sells in vitro diagnostic kits and supporting equipment for pyrazinamide (PZA) susceptibility testing of Mycobacterium tuberculosis. The portfolio includes dry-format 96-well MIC plates using a proprietary broth microdilution method at neutral pH (6.8), a fluorescence-based growth indicator kit, and a manual microplate fluorescence viewbox, all aimed at improving the reliability and speed of PZA drug susceptibility testing.

Product overview

PZA Innovation offers a portfolio of diagnostic products for Pyrazinamide (PZA) susceptibility testing against Mycobacterium tuberculosis. The core portfolio includes the PZA DST Kit, a standard 96-well MIC plate using visible growth-based result interpretation, and the MycoGI PZA DST Kit, which integrates a built-in fluorescence growth indicator for earlier and more objective endpoint determination. Both products utilize a neutral pH (6.8) platform that improves upon conventional acidic-condition testing methods. The Manual Microplate Fluorescence Viewbox serves as an add-on device for reading the fluorescence-based MycoGI plates. All products are designed for research use only and support the company's mission to develop reliable PZA susceptibility testing methods.

Differentiator

Problem solved

Functional benefit

Products and services

• PZA DST Kit A dry-format 96-well PZA MIC plate (Catalog No. PZA2026V2S) designed for quantitative determination of the minimum inhibitory concentration (MIC) of Pyrazinamide against Mycobacterium tuberculosis isolates at neutral pH (6.8) using standardized broth microdilution method (BMM). Uses CLSI-recommended inoculum range (2–8 × 10⁵ CFU/mL) with visible growth-based result interpretation, delivering results within 7–21 days and a 12-month shelf life at 2–8°C. Intended for clinical laboratories and research institutions performing tuberculosis susceptibility testing. For Research Use Only.
• MycoGI PZA DST Kit A dry-format 96-well PZA MIC microdilution plate (Catalog No. PZA2026V2C) integrated with a mycobacterial growth indicator (MycoGI) fluorescence detection system for quantitative MIC determination at neutral pH (6.8). Uses an oxygen-quenched fluorescence sensor to monitor mycobacterial growth, enabling objective MIC endpoint determination with results available within 6–10 days, CLSI inoculum range (2–8 × 10⁵ CFU/mL), and 12-month shelf life at 2–8°C. For Research Use Only.
• Manual Microplate Fluorescence Viewbox A mirrored fluorescence viewing device (Catalog No. PZA2026MV) designed for simple and reliable manual visual reading of fluorescence-based MycoGI DST microplates. Provides enhanced visualization of fluorescent endpoints with improved contrast and readability in a compact laboratory-friendly design (6.3" W × 7" H × 7" L). For use with MycoGI DST products.

Quantifiable outcome

• Reduces PZA susceptibility testing time to 6-10 days with MycoGI fluorescence detection
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Two Research Institutes (Unnamed)coreStrategic or Co-development Partner · 1 January 2024PZA Innovation is collaborating with two research institutes on the NIH NIAID-funded project (R44AI181252) to develop rapid phenotypic PZA susceptibility testing and address systemic limitations in current methods.
• LifeBridge Health BioIncubatorcoreStrategic or Co-development Partner · 1 January 2020PZA Innovation joined LifeBridge Health BioIncubator in 2020, providing access to resources, mentorship, and infrastructure to support early-stage biotech development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Others

• FIND (Foundation for Innovative New Diagnostics): Non-profit that drives adoption of new TB and AMR diagnostics in low- and middle-income countries. Not a commercial competitor but a key channel partner and potential funding/evaluation body for PZA Innovation's clinical pathway.

Broad incumbents

• Qiagen: Offers QuantiFERON-TB Gold for TB infection screening and has expanded into molecular TB resistance testing. Competes for TB diagnostic testing budget in clinical and reference labs.
• bioMérieux: Provides a broad portfolio of clinical microbiology and TB diagnostics, including culture-based DST and the BIOFIRE FilmArray molecular panels. Competes in the same TB diagnostic lab workflow as PZA Innovation.
• Roche Diagnostics: Operates cobas MTB and other molecular TB assays serving high-throughput clinical laboratories. A potential partner or competitor depending on its TB menu expansion plans.
• Abbott (Alere): Provides the RealTime MTB and MTB/RIF molecular assays on the m2000 platform, addressing TB detection and rifampin resistance. Competes for TB diagnostic spend in clinical laboratories.
• Becton, Dickinson and Company (BD): BD's BACTEC MGIT 960 system is the dominant automated phenotypic TB culture and DST platform globally. Most directly comparable to PZA Innovation's phenotypic DST approach, but BD serves a much broader menu of drugs and organisms.
• Hain Lifescience (Bruker): Developer of the GenoType MTBDR line of line-probe assays for TB drug resistance detection. Competes in TB DST via molecular methods rather than the phenotypic approach PZA Innovation is pursuing.
• Cepheid (Danaher): Market-leading molecular TB diagnostics platform (GeneXpert MTB/RIF, MTB/XDR) used in high-burden countries. Directly competes for the same TB DST lab budget as PZA Innovation, but via rapid molecular PCR rather than phenotypic methods.

Emerging players

• QuantuMDx: Develops rapid molecular point-of-care diagnostics including for TB drug resistance. An emerging player competing for next-generation TB DST adoption with similar early-stage commercialization dynamics.

Regional players

• TraumaTec: Smaller developer of mycobacterial culture and DST consumables serving reference and clinical TB labs. Comparable in scale and product focus to PZA Innovation but with a more established European customer base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PZA Innovation